AUS
NZ
UK
CA
USA
IND
Healt
EVE Health Expands Reformulated Drug Development Strategy
March 13, 2026 08:23 PM AEDT| By SamEVE Health Group strengthens its pharmaceutical reformulation strategy with new funding aimed at advancing innovative drug delivery technologies, regulatory development, and intellectual property initiatives targeting major global therapeutic markets...
Immutep Halts Key Lung Cancer Trial, Refocuses Strategy
March 13, 2026 08:09 PM AEDT| By SamImmutep halts its TACTI-004 lung cancer trial following a futility assessment, extending cash runway and prompting a strategic shift in its immunotherapy research pathway and broader oncology development programs.
Telix Trial Safety Update Draws Fresh Market Attention
March 13, 2026 06:01 PM AEDT| By SamTelix Pharmaceuticals advances its oncology pipeline as Phase trial safety data for TLX591-Tx strengthens focus on precision radiopharmaceutical therapies and evolving imaging-driven cancer treatment strategies.
Sonic Healthcare Valuation Debate Gains Market Attention
March 13, 2026 05:35 PM AEDT| By SamSonic Healthcare valuation debate intensifies as revenue growth meets profitability pressure. Explore diagnostics demand trends, regulatory risks, and margin recovery prospects shaping the outlook for this global pathology provider.
ASX 200 Healthcare Stocks Slide as Sector Faces Tough Week
March 13, 2026 04:35 PM AEDT| By SamRecent reporting season updates placed the ASX healthcare sector in focus as biotechnology firms, diagnostic providers, and medical service companies released operational developments and corporate announcements.
ASX 200 Watch: CSL Buy-Back Activity Draws Market Attention
March 13, 2026 11:25 AM AEDT| By SamCSL’s continued share repurchase activity highlights strategic capital management within Australia’s biotechnology sector and reflects how large corporations balance innovation investment with shareholder value initiatives.
ASX 200 Watch: What Immutep’s Efti Trial Shift Means Now
March 13, 2026 10:41 AM AEDT| By SamA clinical trial update from Immutep highlights the challenges of immunotherapy development while reinforcing the ongoing scientific pursuit of innovative cancer treatments within Australia’s biotechnology sector.
ASX Healthcare Buzz: Clinical Milestone Lifts Market Focus
March 13, 2026 10:35 AM AEDT| By SamHighlights,Clinical research updates sparked strong market attention in a healthcare listing,Elevated trading activity highlighted renewed focus on biotechnology progress,Funding developments strengthened visibility around the next stage of medical s...
InteliCare Expands Aged Care Tech With Major Sector Deal
March 12, 2026 09:48 PM AEDT| By SamInteliCare Holdings (ASX:ICR) expands its aged care technology footprint through a multi-year agreement deploying predictive analytics and IoT solutions across Victorian facilities, supporting digital transformation in residential care.
Clarity Pharma Trial Momentum Draws Market Attention
March 12, 2026 08:37 PM AEDT| By SamClarity Pharmaceuticals advances its AMPLIFY clinical trial recruitment, drawing attention to radiopharmaceutical innovation and prostate cancer imaging research while reinforcing industry focus on advanced diagnostic technologies.
Racura Oncology Expands Share Base With New ASX Quotation
March 12, 2026 04:40 PM AEDT| By SamA biotechnology company applies to quote additional ordinary shares on the Australian exchange, reflecting routine capital structure management while continuing research programs focused on innovative cancer treatment development.
HeraMED Share Expansion Draws Attention Across ASX Market
March 12, 2026 11:49 AM AEDT| By SamHeraMED expands its listed share base through the quotation of new equity, illustrating how capital structure adjustments influence liquidity and transparency across Australia’s healthcare technology segment.
Cyclopharm Share Update: What the New ASX Listing Move Signals
March 12, 2026 11:41 AM AEDT| By SamCyclopharm progresses a routine share quotation step on the Australian exchange, highlighting how healthcare technology companies manage equity structures while maintaining engagement with the broader Australian capital market.
ASX 200 Faces Pressure as Strait of Hormuz Tensions Rise
March 12, 2026 11:08 AM AEDT| By SamRising geopolitical tensions and evolving lithium demand are shaping Australian market sentiment. Liontown Resources highlights the growing importance of battery minerals as global energy systems transition toward electrification.
ASX Compliance Action Puts Spotlight on OncoSil Securities
March 11, 2026 05:25 PM AEDT| By SamExchange oversight temporarily paused quotation of a specialised healthcare security class, highlighting the importance of listing rule compliance, transparency, and structured governance within Australia’s regulated public market environment.
Imugene Capital Raise Drives Azer-Cel Cancer Program Forward
March 11, 2026 05:22 PM AEDT| By SamImugene Ltd launches a major capital raise to support azer-cel cancer therapy development, expand clinical trials, and strengthen its immuno-oncology pipeline while advancing research within Australia’s biotechnology sector.
Clarity Pharma’s New Share Move Grabs ASX Attention
March 11, 2026 04:20 PM AEDT| By SamA biotechnology company’s new share quotation request highlights ongoing capital activity within Australia’s healthcare innovation sector while reflecting the strategic role equity instruments play in supporting research and development programs.
Biotech Momentum on ASX: Could This Medical Tech Story Surge?
March 11, 2026 12:37 PM AEDT| By SamMetal Powder Works has introduced additional ordinary shares for quotation on the ASX, expanding its capital base and illustrating how evolving capital structures influence liquidity and trading activity.
Imugene Trial Update Sparks Hope in Cancer Immunotherapy
March 10, 2026 07:42 PM AEDT| By SamImugene’s experimental immunotherapy gains attention after a trial participant enters remission. The development highlights progress in advanced lymphoma research and evolving cancer treatment approaches.
CleanSpace Share Quotation Update Highlights ASX Market
March 10, 2026 06:10 PM AEDT| By SamA listed safety technology company applied for quotation of additional ordinary shares, reflecting routine compliance with exchange regulations while highlighting ongoing developments within Australia’s evolving public market landscape.
Advertise your brand on Kalkine Media